Summary
We have previously shown that cyclosporin A (CsA) produces high bone remodeling with resorption exceeding formation and loss of bone volume in the rat. This may have important clinical implications where CsA is widely used in organ transplantation. 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) is a bone mineralizing hormone which also has immune modifying properties. Consequently, we studied the effect of combined CsA and 1,25(OH)2D3 administration over 28 days in four groups of rats. Group A received vehicle (n=10), group B CsA (15 mg/kg) (n=10) alone, group C 1,25(OH)2D3 plus CsA (n=15), and group D 1,25(OH)2D3 alone (20 ng/100 g) (n=15). Rats were bled periodically at day 0, 7, 14, and 28 and Ca, parathyroid hormone (PTH), 1,25(OH)2D, osteocalcin (bone Gla-protein, BGP), BUN, and creatinine were measured. Rats were sacrificed on day 28 and bones were examined histomorphometrically. Compared to controls, CsA resulted in significant elevation of BGP and a transient increase in 1,25(OH)2D with excess bone remodeling and loss of bone volume. 1,25(OH)2D3 administration produced hypercalcemia, a significant rise in BGP, with suppression of PTH and increased osteoid volume. Combined therapy prevented the loss of bone volume probably due to increased osteoid tissue and enhanced osteoblast activity. Renal dysfunction, a side-affect of CsA, was not a factor. In conclusion, 1,25(OH)2D3 combined with CsA restores bone volume which is accompanied by increases in serum calcium and BGP.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB (1984) Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Int Med 101:667–682
Kahan BD (1987) Transplantation of the heart. Immunosuppressive therapy with cyclosporine for cardiac transplantation. Circulation 75:40–55
Skyler J (1987) Cyclosporine in insulin-dependent diabetes: effects on islet beta cell function. 2nd Int Congr on Cyclosporine, Washington, DC
Whiting PH, Thomson AW, Simpson TG (1985) Cyclosporine: toxicity, metabolism and drug interactions—implications from animal studies. Transplant Proc XVII, pp 134–144
Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S (1988) Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 123:2571–2577
Aubia J, Masramon J, Serrano S, Lloveras J, Marinoso LL (1988) Bone histology in renal transplant recipients receiving cyclosporine. Lancet 1:1048
Bourbigot B, Moal MC, Cledes J (1988) Bone histology in renal transplant recipients receiving cyclosporin. Lancet 1:1048
Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon M, Thomas S (1989) The effect of cyclosporine A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124:2179–2184
Warren SB, Pelker RP, Friedlaender GE (1985) Effects of short-term cyclosporin A on biomechanical properties of intact and fractured bone in the rat. J Orthop Res 3:96–100
Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T (1981) Differentiation of mouse myeloid leukemia cells induced by 1,25 dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:4990–4994
Jowell PS, Epstein S, Fallon MD, Reinhardt TA, Ismail F (1987) 1,25 dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone gla protein and bone histomorphometry. Endocrinology 120:531–536
Toverud SU, Boass A, Gardner SC, Endress DB (1986) Circulating parathyroid hormone concentrations in normal and vitamin-D-deprived rat pups determined with N-terminal-specific radioimmunoassay. Bone Miner 1:145–155
Stewart PJ, Green OC, Stern PH (1986) Cyclosporin A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Miner Res 1:285–291
Ismail F, Epstein S, Fallon MD, Thomas SB, Reinhardt TA (1988) Serum bone gla protein and the vitamin D endocrine system in the oophorectomized rat. Endocrinology 122:624–630
Cavallini M, Halberg F, Cornelissen G, Enrichens F, Margarit C (1986) Organ transplantation and broader chronotherapy with implantable pump and computer programs for marker rhythm assessment. J Controlled Release 3:313
Keown PA, Stiller CR (1987) Cyclosporine: a double-edged sword. Hosp Pract [Off] 22:207–220
Centrella M, Canalis E (1985) Local regulators of skeletal growth: a perspective. Endocr Rev 6:544–551
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 319:516–518
Heath JK, Saklatvala J, Meikle MC, Atkinson SJ, Reynolds JJ (1985) Pig interleukin 1 (catabolin) is a potent stimulator of bone resorption in vitro. Calcif Tissue Int 37:95–97
Ikekawa N (1988) Chemical synthesis of vitamin D analogs with selective biological activities. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV (eds) Vitamin D molecular cellular and clinical endocrinology. pp 25–33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Epstein, S., Schlosberg, M., Fallon, M. et al. 1,25 dihydroxyvitamin D3 modifies cyclosporine-induced bone loss. Calcif Tissue Int 47, 152–157 (1990). https://doi.org/10.1007/BF02555980
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02555980